Tvardi Therapeutics is trading at $0.84, a change of -10.43%, with no clear company-specific announcement identified to explain the October 26 decline.
- The latest listed company release was the October 14 conference announcement.
- The broader market was higher, so market-wide weakness does not explain the drop; the available information does not establish another catalyst.
- The decline follows several weaker closes, but that trend does not establish the cause of today’s move.